目的观察静脉注射用人免疫球蛋白佐治重症肺炎支原体肺炎的临床疗效及不良反应。方法选择2010年10月-2011年11月重症肺炎支原体肺炎113例,随机分为治疗组和对照组,治疗组56例和对照组57例,两组患儿均先后给予红霉素、阿奇霉素序贯治疗及对症治疗,疗程2周左右,治疗组在以上治疗基础上加静脉注射用人免疫球蛋白400 mg/(kg.d),连用3 d。结果治疗组发热、咳嗽、干啰音、湿啰音消失时间分别为(2.1±1.3)d、(4.2±1.2)d、(2.5±1.2)d、(3.6±1.1)d,对照组分别为(3.3±1.0)d、(5.6±2.3)d、(4.3±2.5)d、(5.4±1.8)d,两组比较差异有统计学意义(P<0.01)。结论静脉注射用人免疫球蛋白佐治重症肺炎支原体肺炎,临床疗效确切,无不良反应。 Objective To observe the clinical efficacy and adverse reactions of intravenous immunoglobulin in patients with severe Mycoplasma pneumoniae pneumonia. Methods A total of 113 cases of severe Mycoplasma pneumoniae pneumonia from October 2010 to November 2011 were randomly divided into treatment group and control group, 56 cases in treatment group and 57 cases in control group. Erythromycin, azithromycin Consistently treated and symptomatic treatment, treatment for 2 weeks, the treatment group in addition to the above treatment plus intravenous immunoglobulin 400 mg / (kg.d), once every 3 d. Results The disappearance time of fever, cough, dry rales and wet rales were (2.1 ± 1.3) days, (4.2 ± 1.2 days), (2.5 ± 1.2 days) and (3.6 ± 1.1 days) respectively in the treatment group and (3.3 ± 1.0) days, (5.6 ± 2.3) days, (4.3 ± 2.5) days and (5.4 ± 1.8) days respectively. There was significant difference between the two groups (P <0.01). Conclusion Intravenous injection of human immunoglobulin in patients with severe Mycoplasma pneumoniae pneumonia, clinical curative effect, no adverse reactions.